Sending Office: Honorable Colleen Hanabusa
Sent By:
Robert.Zane@mail.house.gov

Support liver cancer and hepatitis B research in Defense appropriations!

FY 19 Language Request

Deadline: THURSDAY MARCH 15 @ NOON

Co-signers: Jones, Danny DavisClarke, DeSaulnier, Cohen, Bobby Scott, Velázquez, Shea-Porter, Jayapal, Matsui, Hastings, Jackson Lee, Vela, Grijalva, Schiff, Sewell, Gabbard, Khanna, Kuster, McNerney, Norton, Chu

Dear colleagues,

Over the past 15 years, cancer death rates for men and women of all major racial and ethnic populations in the United States have declined, with liver cancer being the notable exception.  Former Director of the CDC’s Division of Viral Hepatitis, Dr. John
W. Ward, stated that liver cancer is “one of the few areas where our nation is losing the battle against cancer – but it doesn’t have to be this way.” 

HBV is a leading cause of cirrhosis and liver cancer, one of the high-mortality cancers in which five-year survival rates are below 50 percent.  Unsurprisingly, as HBV infection rates increased, so too has the rate of new liver cancer cases.  Between 2003
and 2012, rates of new liver cancer cases increased by 38 percent.  The CDC’s 2016 report on the status of cancer showed that, while death rates for other cancers among both men and women continued to decline, death rates from liver cancer have increased the
most. 

Funding for liver cancer and HBV research helps address two of the most pressing public health challenges in the United States.  Please join us in supporting the inclusion of liver cancer and hepatitis B (HBV) on the list of eligible funding areas
under the Peer Reviewed Cancer Research Program and the Peer Reviewed Medical Research Program in the FY 2019 Defense Appropriations bill. 

If you have any questions or would like to sign on, please contact Robert.zane@mail.house.gov (Hanabusa) or Joseph.Knowles@mail.house.gov (Fitzpatrick).

Sincerely,

Colleen Hanabusa                                            Brian Fitzpatrick
Member of Congress                                       Member of Congress


Dear Chairwoman Granger and Ranking Member Visclosky,

Over the past 15 years, cancer death rates for men and women of all major racial and ethnic populations in the United States have declined, with liver cancer being the notable exception.  Former Director of the CDC’s Division of Viral Hepatitis, Dr. John
W. Ward, stated that liver cancer is “one of the few areas where our nation is losing the battle against cancer – but it doesn’t have to be this way.” 

To embolden our country’s fight against liver cancer and hepatitis B, one of its leading causes, we respectfully request that you continue to include liver cancer and hepatitis B (HBV) on the list of eligible funding areas under the Peer Reviewed Cancer
Research Program and the Peer Reviewed Medical Research Program in the FY 2019 Defense Appropriations bill. 

Funding for liver cancer and HBV research helps address two of the most pressing public health challenges in the United States.  Estimates of the number of people with HBV are as high as 2.2 million people, reflecting hundreds of thousands who remain unaware
of their infection status.  A recent study at the Philadelphia VA Medical Center revealed that HBV infection is twice as common in the veteran population as in the general population of the country, while only 15 percent of veterans have been tested for the
disease. 

HBV is a leading cause of cirrhosis and liver cancer, one of the high-mortality cancers in which five-year survival rates are below 50 percent.  Unsurprisingly, as HBV infection rates increased, so too has the rate of new liver cancer cases.  Between 2003
and 2012, rates of new liver cancer cases increased by 38 percent.  The CDC’s 2016 report on the status of cancer showed that, while death rates for other cancers among both men and women continued to decline, death rates from liver cancer have increased the
most. 

Targeted efforts to address HBV and liver cancer through sound public health policy and research will go a long way in relieving this public health challenge that affects millions of Americans.  On behalf of those Americans living and fighting HBV and liver
cancer and their loved ones, we encourage this committee to include liver cancer and HBV on the Department of Defense’s peer reviewed program lists. 

We appreciate this committee’s consideration of our request.

Sincerely,

Colleen Hanabusa                                                       Brian Fitzpatrick
Member of Congress                                                   Member of Congress

Related Legislative Issues

Selected legislative information: Appropriations, Armed Services, Family Issues, Government, HealthCare, Labor, Science, Social Security, Veterans

icon eDC logo e-Dear Colleague version 2.0